Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 6/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489867 | 0.79 | BRD4 (0.61) | BRD4IGF1RMAPTJAK2TYK2 | |
| SCHEMBL30306480 | 0.76 | EGFR (0.60) | BRD4JAK2KDRAURKASCN9A | |
| SCHEMBL17526251 | 0.75 | BRD4 (1.00) | BRD4IGF1RAURKA | |
| SCHEMBL3204027 | 0.75 | BRD4 (0.50) | BRD4IGF1RJAK2TYK2SYK | |
| SCHEMBL2747321 | 0.73 | MAPT (0.68) | BRD4MAPT | |
| SCHEMBL13756873 | 0.73 | BRD4 (0.52) | BRD4IGF1RMAPTJAK2SYK | |
| SCHEMBL1735409 | 0.72 | MAPT (0.65) | BRD4IGF1RMAPTJAK2 | |
| SCHEMBL4283753 | 0.72 | BRD4 (0.67) | BRD4IGF1RJAK2AURKA | |
| SCHEMBL17526147 | 0.72 | BRD4 (1.00) | BRD4IGF1R | |
| SCHEMBL3226666 | 0.71 | SCN9A (0.54) | AURKASCN9AKCNH2SCN5ACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | BRD4 1/4885IGF1R 975/4885MAPT 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.